<DOC>
	<DOCNO>NCT02481219</DOCNO>
	<brief_summary>This study design determine optimal bowel preparation regimen PillCam® COLON 2 Capsule Endoscopy System ( CCE ) procedures average risk patient . Patients randomize receive one two bowel preparation regimens prior PillCam CCE .</brief_summary>
	<brief_title>Optimization Bowel Preparation Regimen PillCam® COLON 2 Capsule Endoscopy Procedure</brief_title>
	<detailed_description>This multicenter , prospective , consecutive , randomize study . Average-risk subject undergo CCE without optical colonoscopy consecutively enrol randomized 1:1 receive one two bowel preparation regimens prior PillCam CCE . Subjects enrol 5-10 clinical site United States . Subjects meet eligibility criterion screen study participation baseline visit evaluated procedure day capsule excretion . A telephone follow-up conduct 5 9 day post-capsule ingestion verify capsule excretion , assess patient well-being , capture adverse event .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<mesh_term>Bisacodyl</mesh_term>
	<criteria>1 . Subject 50 75 year age . 2 . Subject classified average risk per American Gastroenterological Association Guidelines Colorectal Cancer Screening : Individuals without personal family history colorectal cancer ( CRC ) adenoma , inflammatory bowel disease , highrisk genetic syndrome . 3 . Subject willing able participate study procedure understand sign inform consent . 1 . Subject history polyp ( include identify computed tomography [ CT ] , optical colonoscopy , sigmoidoscopy , etc. ) . 2 . Subject history negative colon assessment ( include CT , optical colonoscopy , sigmoidoscopy etc . ) within 5 year subject would define require screen time frame . 3 . Subject suspect diagnosed hematochezia , melena , iron deficiency without anemia , rectal bleeding , include positive fecal occult blood test variety . 4 . Subject condition believe increase risk capsule retention suspect know bowel obstruction , stricture , fistula . 5 . Subject dysphagia swallow disorder . 6 . Subject serious medical condition would increase risk associate capsule colonoscopy severe screen would benefit . 7 . Subject cardiac pacemaker implant electromedical device . 8 . Subject expect undergo MRI examination within 7 day ingestion capsule . 9 . Subject clinical evidence renal disease , include clinically significant laboratory abnormality renal function within past 6 month , time past test within last 6 month , define creatinine , blood urea nitrogen ( BUN ) , and/or glomerular filtration rate ( GFR ) outside local laboratory reference range . 10 . Subject know gastrointestinal motility disorder . 11 . Subject allergy know contraindication medication preparation agent used procedure describe relevant instruction use . 12 . Subject comorbidities , opinion investigator , appropriate study subject estimate life expectancy le 6 month . 13 . Subject consider part vulnerable population ( e.g . prisoner without sufficient mental capacity ) . 14 . Subject pregnant , suspected pregnant , actively breastfeed . Females childbearing potential require provide either urine pregnancy test serum pregnancy test part participant 's standard care regardless participation study ( except subject surgically sterile postmenopausal least two year ) . 15 . Subject participate investigational drug device research study within 30 day enrollment may interfere subject 's safety ability participate study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Polyps</keyword>
	<keyword>Capsule endoscopy</keyword>
	<keyword>Bowel preparation regimen</keyword>
	<keyword>Average risk patient colorectal cancer screen</keyword>
</DOC>